These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 28947416)
1. Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. George JT; Jolly MK; Xu S; Somarelli JA; Levine H Cancer Res; 2017 Nov; 77(22):6415-6428. PubMed ID: 28947416 [TBL] [Abstract][Full Text] [Related]
2. Stability of the hybrid epithelial/mesenchymal phenotype. Jolly MK; Tripathi SC; Jia D; Mooney SM; Celiktas M; Hanash SM; Mani SA; Pienta KJ; Ben-Jacob E; Levine H Oncotarget; 2016 May; 7(19):27067-84. PubMed ID: 27008704 [TBL] [Abstract][Full Text] [Related]
3. NRF2 activates a partial epithelial-mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype. Bocci F; Tripathi SC; Vilchez Mercedes SA; George JT; Casabar JP; Wong PK; Hanash SM; Levine H; Onuchic JN; Jolly MK Integr Biol (Camb); 2019 Jun; 11(6):251-263. PubMed ID: 31329868 [TBL] [Abstract][Full Text] [Related]
4. SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses Prostate Cancer Growth and Migration. Eguchi T; Csizmadia E; Kawai H; Sheta M; Yoshida K; Prince TL; Wegiel B; Calderwood SK Cells; 2022 Dec; 11(24):. PubMed ID: 36552758 [TBL] [Abstract][Full Text] [Related]
5. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527 [TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. Tan TZ; Miow QH; Miki Y; Noda T; Mori S; Huang RY; Thiery JP EMBO Mol Med; 2014 Oct; 6(10):1279-93. PubMed ID: 25214461 [TBL] [Abstract][Full Text] [Related]
8. Testing the gene expression classification of the EMT spectrum. Jia D; George JT; Tripathi SC; Kundnani DL; Lu M; Hanash SM; Onuchic JN; Jolly MK; Levine H Phys Biol; 2019 Jan; 16(2):025002. PubMed ID: 30557866 [TBL] [Abstract][Full Text] [Related]
9. MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. Su L; Luo Y; Yang Z; Yang J; Yao C; Cheng F; Shan J; Chen J; Li F; Liu L; Liu C; Xu Y; Jiang L; Guo D; Prieto J; Ávila MA; Shen J; Qian C Cancer Res; 2016 Sep; 76(17):5054-67. PubMed ID: 27364559 [TBL] [Abstract][Full Text] [Related]
10. Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis. Garg M Expert Rev Mol Med; 2017 Mar; 19():e3. PubMed ID: 28322181 [TBL] [Abstract][Full Text] [Related]
11. Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Jolly MK; Boareto M; Huang B; Jia D; Lu M; Ben-Jacob E; Onuchic JN; Levine H Front Oncol; 2015; 5():155. PubMed ID: 26258068 [TBL] [Abstract][Full Text] [Related]
12. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976 [TBL] [Abstract][Full Text] [Related]
13. Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages. Wang D; Haley JD; Thompson P BMC Cancer; 2017 Dec; 17(1):830. PubMed ID: 29212455 [TBL] [Abstract][Full Text] [Related]
14. Hybrid Epithelial/Mesenchymal State in Cancer Metastasis: Clinical Significance and Regulatory Mechanisms. Liao TT; Yang MH Cells; 2020 Mar; 9(3):. PubMed ID: 32143517 [TBL] [Abstract][Full Text] [Related]
15. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. Hance MW; Dole K; Gopal U; Bohonowych JE; Jezierska-Drutel A; Neumann CA; Liu H; Garraway IP; Isaacs JS J Biol Chem; 2012 Nov; 287(45):37732-44. PubMed ID: 22989880 [TBL] [Abstract][Full Text] [Related]
16. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858 [TBL] [Abstract][Full Text] [Related]
17. Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression. Sinha D; Saha P; Samanta A; Bishayee A Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33207810 [TBL] [Abstract][Full Text] [Related]
18. The crosstalk between metabolic reprogramming and epithelial-mesenchymal transition and their synergistic roles in distant metastasis in breast cancer. Yu L; Chen Y; Chen Y; Luo K Medicine (Baltimore); 2024 Jun; 103(24):e38462. PubMed ID: 38875364 [TBL] [Abstract][Full Text] [Related]
19. Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum. Chakraborty P; George JT; Tripathi S; Levine H; Jolly MK Front Bioeng Biotechnol; 2020; 8():220. PubMed ID: 32266244 [TBL] [Abstract][Full Text] [Related]
20. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]